NEW YORK, August 11 (GenomeWeb News) - Benitec today said that it has settled a patent infringement case against Ambion, and that Ambion has taken a world-wide nonexclusive license to make and sell ddRNAi (DNA-directed RNAi) -based products as part of the settlement agreement.
Benitec said that the settlement "completely resolves all claims and counterclaims" asserted in a patent infringement dispute that began when the company filed suit against Ambion in March.
Financial details of Ambion's licensing agreement were not disclosed.
Benitec has also accused two other firms -- Nucleonics and Genscript -- of infringing Benitec's ddRNAi patent, US Patent No. 6,573,099, entitled "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene." Benitec did not provide information on the status of these lawsuits.
Benitec currently holds seven issued patents in five jurisdictions, including the